Status:
COMPLETED
Observational Safety Study of Etanercept (Enbrel) for Treatment of Psoriasis
Lead Sponsor:
Amgen
Conditions:
Psoriasis
Eligibility:
All Genders
18+ years
Brief Summary
This is an observational safety study tracking psoriasis patients on etanercept (Enbrel) for 5 years.
Detailed Description
This is a prospective, multi-center, observational surveillance registry to evaluate data on the long-term safety of etanercept (Enbrel) use in the treatment of psoriasis.
Eligibility Criteria
Inclusion
- Patients with plaque psoriasis
Exclusion
- Prior exposure to any tumor necrosis factor (TNF)-inhibitor
- Patients for whom Enbrel is contraindicated
- Patients currently enrolled in or has not yet completed at least 30 days since ending other investigational drug study.
Key Trial Info
Start Date :
May 1 2006
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
February 8 2013
Estimated Enrollment :
2511 Patients enrolled
Trial Details
Trial ID
NCT00322439
Start Date
May 1 2006
End Date
February 8 2013
Last Update
June 28 2018
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.